arts
FDA moves ahead with safety study of abortion pill mifepristone
By Michael Kaplan at CBS4 Miami
· June 5, 2026
· 3 min read
The Food and Drug Administration is moving ahead with a safety study of the abortion pill mifepristone, a senior FDA official confirmed to CBS News, a step that could create a path for the Trump administration to restrict access to the medication.It will be a retrospective study of hundreds of thous
Key takeaway A White House spokesperson said it has been underway for months and is moving from a new phase focused on analyzing data the agency has already collected.
Why this matters in The Miami
In Miami, where Latin American and Caribbean communities have a significant presence, access to reproductive healthcare is a pressing concern. The FDA's safety study of mifepristone may have implications for the city's residents, many of whom may rely on the medication for abortion services. Miami's diverse population, with its strong ties to Latin America and the Caribbean, may be particularly affected by any changes to the availability of mifepristone. The city's healthcare providers, including those in Little Havana and other neighborhoods, may need to adapt to new regulations or restrictions on the medication. As the study moves forward, Miami's residents and healthcare providers will be watching closely to see how the results may impact access to reproductive healthcare in the city. The outcome of the study could also have significant implications for Miami-Dade County's public health policies and services.
About this story
Original reporting by CBS4 Miami . The Miami surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit CBS4 Miami . Have a tip or correction? Contact our newsroom .
Category: arts ·
Published: June 5, 2026 ·
Source: CBS4 Miami ·
Reading time: 3 min
newsletter" aria-label="Newsletter signup" style="margin:24px 0;padding:20px 24px;background:linear-gradient(135deg,#1e3a5f 0%,#2d5a8c 100%);border-radius:10px;color:#fff">
Get more The Miami stories like this
Free weekly briefing covering arts and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? The Food and Drug Administration is moving ahead with a safety study of the abortion pill mifepristone, a senior FDA official confirmed to CBS News, a step that could create a path for the Trump administration to restrict access to the medication.It will be a retrospective study of hundreds of thous
When was this published? This article was first published on June 5, 2026 by CBS4 Miami and curated for The Miami readers.
Who reported this story? This story was reported by Michael Kaplan at CBS4 Miami. To learn more about how The Miami selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more arts coverage from The Miami, or browse our daily briefing and topic hubs .
← Back to all news
More arts →
Today’s briefing
Subscribe to newsletter